Acumen Pharmaceuticals, Inc. (ABOS)
1.78
+0.09
(+5.33%)
USD |
NASDAQ |
Oct 19, 16:00
1.78
0.00 (0.00%)
After-Hours: 20:00
Acumen Pharmaceuticals Enterprise Value : 43.66M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 43.66M |
| October 15, 2026 | 42.21M |
| October 14, 2026 | 47.64M |
| October 13, 2026 | 52.70M |
| October 12, 2026 | 67.52M |
| October 09, 2026 | 76.20M |
| October 08, 2026 | 73.31M |
| October 07, 2026 | 73.31M |
| October 06, 2026 | 68.25M |
| October 05, 2026 | 75.48M |
| October 02, 2026 | 68.97M |
| October 01, 2026 | 71.14M |
| September 30, 2026 | 81.99M |
| September 29, 2026 | 83.80M |
| September 28, 2026 | 87.77M |
| September 25, 2026 | 83.43M |
| September 24, 2026 | 83.07M |
| September 23, 2026 | 88.13M |
| September 22, 2026 | 113.08M |
| September 21, 2026 | 108.74M |
| September 18, 2026 | 113.08M |
| September 17, 2026 | 107.30M |
| September 16, 2026 | 110.19M |
| September 15, 2026 | 130.44M |
| September 14, 2026 | 123.21M |
| Date | Value |
|---|---|
| September 11, 2026 | 132.61M |
| September 10, 2026 | 128.27M |
| September 09, 2026 | 127.55M |
| September 08, 2026 | 149.96M |
| September 04, 2026 | 151.41M |
| September 03, 2026 | 144.90M |
| September 02, 2026 | 145.62M |
| September 01, 2026 | 132.61M |
| August 31, 2026 | 127.55M |
| August 28, 2026 | 132.61M |
| August 27, 2026 | 140.56M |
| August 26, 2026 | 137.67M |
| August 25, 2026 | 145.62M |
| August 24, 2026 | 143.82M |
| August 21, 2026 | 149.96M |
| August 20, 2026 | 152.13M |
| August 19, 2026 | 149.24M |
| August 18, 2026 | 119.59M |
| August 17, 2026 | 113.81M |
| August 14, 2026 | 114.53M |
| August 13, 2026 | 105.85M |
| August 12, 2026 | 102.96M |
| August 11, 2026 | 100.07M |
| August 10, 2026 | 97.17M |
| August 07, 2026 | 97.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 41.43B |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.72M |
| Total Expenses (Quarterly) | 32.72M |
| EPS Diluted (Quarterly) | -0.4528 |
| Earnings Yield | -91.71% |
| Normalized Earnings Yield | -91.52 |